In nonclinical studies and a Phase IIa clinical st

Quote:

---

In nonclinical studies and a Phase IIa clinical study of the combination therapy, the treatment was effective in reducing liver fat

---

Fat can be one of the factors that induce an inflammatory state but there are bound to be other factors. Most NASH drugs have targeted fat rather than the inflammation itself and they've all failed. Leronlimab targets inflammation but can also decrease white fat (bad) and increase brown fat (good).